TrialThe Journal of clinical endocrinology and metabolism2021

EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.

Odelia Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.